Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that predictably familiar routine of meetings, deadlines, and the like has, of course, returned. Although the usual crush of things to do may be a bit lighter for some, given that some holidays are just around the bend. Nonetheless, we are pursuing our usual routine of brewing cups of stimulation and foraging for interesting items. On that note, here are some tidbits. Hope your day goes well and do keep in touch.

The Food and Drug Administration expanded the approval of Vascepa, a fish-oil-derived medicine, to allow Amarin (AMRN) to say it prevents heart attacks, strokes, and related health problems in people who are at high cardiovascular risk, STAT notes. The approval reverses decades of mixed results for fish-oil-based drugs and could result in Vascepa being prescribed to millions of patients, potentially resulting in a windfall for the company. But the FDA decided to limit the use of Vascepa more than Amarin had initially requested.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!